Lugano, Switzerland/Woodcliff Lake, NJ (ots) - Helsinn Group and Eisai Inc. announced today that the U.S. Food and Drug Administration (FDA) has agreed to the safety and efficacy protocols for Phase III trials with an investigational oral fixed-dose combination of netupitant and palonosetron in the prevention ...
San Francisco, USA and Freising, Germany (ots) - Takeda San Francisco (TSF) and Pieris AG have signed a drug discovery partnership agreement under which Pieris will apply its Anticalin® scaffold technology to deliver protein therapeutic candidates to Takeda, both companies announced today. The deal initially will focus on first-in-class drug discovery efforts ...
Lugano, Switzerland (ots) - Helsinn Birex Pharmaceuticals Ltd, has been assigned world-wide rights, title and interest in Klean-Prep®, excluding Canada, and an exclusive license for the U.S. Helsinn, a pharmaceutical group based in Lugano, Switzerland today announced that it has entered into an agreement ...
Ittigen, Berne (ots) - Pevion Biotech AG today announced positive preliminary results from a Phase I study of PEV7, the first vaccine against recurrent vulvovaginal candidiasis (RVVC). Also known as chronic recurrent thrush, RVVC is a highly debilitating condition, which affects an estimated 3-6% of women ...
Bern (ots) - Lonza AG in Visp has entered into a partnership with BKW FMB Energy Ltd (BKW) in the field of energy logistics and procurement management. Lonza plans to purchase its energy - around 500 GWh per year - on the free market in future, and has selected BKW as its partner of preference. BKW has contracted to support Lonza AG with its energy procurement strategy and sustainably implement the related ...
Lugoano, Switzerland/Melbourne, Australia (ots) - Australians can now access a new drug to prevent acute (and delayed phase) nausea and vomiting which may occur in cancer patients undergoing chemotherapy1. This follows an agreement between the Swiss pharmaceutical group Helsinn and Specialised Therapeutics ...
Lugano (ots) - New data presented at the ESMO Milan 2010 Congress show a better control of nausea and vomiting with palonosetron versus granisetron in patients undergoing cisplatin or anthracycline plus cyclophosphamide based regimens. Palonosetron superior efficacy is statistically significant in nausea control, following Highly Emetogenic Chemotherapy, in the ...
Freising-Weihenstephan (ots) - Pieris AG announced today the signature of a collaboration and license agreement with both Sanofi-Aventis and Sanofi Pasteur, the vaccines division of the sanofi-aventis Group (EURONEXT: SAN and NYSE: SNY), under which Pieris will apply its proprietary Anticalin technology to ...
Lugano (ots) - The Minister for Finance, Mr. Brian Lenihan T.D. today performed the official opening of the centre which will play a significant role in Helsinn group's pipeline of new products. The Swiss pharmaceutical group Helsinn announced the official opening, performed today by the Minister for Finance, Mr. Brian Lenihan T.D, of its new R&D Centre of ...
Lugano (ots) - Helsinn's second-generation 5-HT3 RA Aloxi expands its presence in Asia through the Agreement signed with Mundipharma Helsinn Healthcare SA and Mundipharma International Corporation Ltd. announce the signature of a Distribution and Licensing Agreement for Helsinn's product palonosetron in Malesia, Philippines and Singapore. Aloxi® is a ...
Jena (ots) - In 2009 the Patents Court of the High Court, Chancery Division, decided that Occlutech's range of Figulla ASD and PFO occluders do not infringe the U.K. part of European Patent 0 808 138. AGA Medical decided to appeal against this decision. The U.K. Court of Appeal (civil division) in London announced its decision confirming that said Figulla ASD and PFO occluders do not infringe said patent. AGA asked ...
Freising-Weihenstephan (ots) - Pieris AG announced today the initiation of a Phase I clinical trial in cancer patients for its lead program, PRS-050, an anti-VEGF Anticalin. The trial is an open-label, dose-escalating evaluation of the compound's safety and tolerability in patients with solid tumors. ...
Lugano, Switzerland/Woodcliff Lake, NJ, USA (ots) - Helsinn Healthcare S.A. and Eisai Inc. today announce the signing of a licensing agreement granting Eisai Inc. commercialization rights for a new product for potential use in the prevention of chemotherapy-induced nausea and vomiting (CINV) in the United ...
Geneva (ots) - PEARL I trial meets primary efficacy and safety endpoints / PregLem preparing for submission to the European Medicines Agency in 2010 PregLem, the European specialty biopharmaceutical company focused on women's reproductive medicine, announces positive Phase III data from its second pivotal study (PEARL I) for its lead product Esmya (ulipristal acetate), as an effective treatment for uterine ...
Lugano (ots) - The second generation 5-HT3 receptor antagonist palonosetron, already approved as an intravenous solution formulation in more than 60 countries worldwide including US, EU and Japan, obtains the European Marketing Authorization for 0.5 mg oral capsules Palonosetron 0.5 mg soft gelatine capsule oral formulation has been approved by the EMA (European Medicine Agency) for the prevention of nausea and ...
Lugano (ots) - New therapeutic option for the management of painful symptoms of oral mucositis in the oncology setting soon available for Swiss patients Helsinn, the pharmaceutical group based in Lugano, and Vifor Pharma, are pleased to announce that a Distribution & Licensing Agreement for Helsinn's product Gelclair in Switzerland has been signed recently. ...
Lugano, Switzerland / Tokyo, Japan (ots) - Helsinn Healthcare SA, Switzerland, and Taiho Pharmaceutical Co., Ltd., Japanese licensee of Helsinn's second generation 5-HT3 receptor antagonist palonosetron, announce the launch of Aloxi® injection today. Aloxi was developed in Japan by Taiho in close cooperation with Helsinn, based on the license agreement between Taiho and Helsinn of January 2004, and its marketing ...
Düsseldorf (ots) - - Group sales in the first quarter up 1.4% on like-for-like basis - Profit from operations grew by 34% to EUR 12.3m - Reiteration of guidance for the financial year 2010 Gerresheimer AG has got off to a good start in the new financial year. In the first quarter (December 2009 to February 2010), sales increased by 1.4% on a like-for-like basis and amounted to EUR 224.8m. ...
Zug (ots) - The Swiss AmVac AG, a biopharmaceutical company located in Zug, has made significant advances in the manufacture and production of its vaccine candidate against RSV over the last few months. This vaccine candidate is based on the new Sendai vector technology for which Max-Planck-Innovations GmbH has acquired the exclusive licence. This technology, which has been developed by Prof. Wolfgang Neubert's ...
Heidelberg (ots) - SYGNIS Pharma AG (Frankfurt: LIO; ISIN DE0005043509; Prime Standard) today reports financial results for the third quarter and the first nine months of the fiscal year 2009/2010 ended December 31, 2009. Financials - Cash including marketable securities amounted to EUR16.4 million as of December 31, 2009 (EUR26.0 million Q3 2008/2009). Long term financial liabilities ...
Lausanne (ots) - Debiopharm Group[TM] (Debiopharm), a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs, today announced the signature of an exclusive licence agreement with Novartis for the development, manufacture ...
Paris/Lausanne (ots) - Ipsen (Euronext: FR0010259150; IPN), an innovation-driven global specialty pharmaceutical group and Debiopharm Group (Debiopharm), a Swiss- based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs, announce ...
Tokyo, Japan and Edison, N.J. (ots) - First Patient Randomized and Dosed in New Trial with Factor Xa Inhibitor, Edoxaban Daiichi Sankyo Company, Limited (TSE: 4568), announced today that it has initiated a new large-scale pivotal Phase III trial for edoxaban, its investigational oral Factor Xa inhibitor. ...
Lugano/Tokyo, Japan (ots) - The second generation 5-HT3 receptor antagonist palonosetron available in more than 50 countries worldwide, including US, EU and Japan Today, Taiho Pharmaceutical Co., Ltd., Japanese licensee of Helsinn's second generation 5-HT3 receptor antagonist palonosetron, gained marketing approval in Japan for this drug indicated for the ...
Lugano (ots) - Giorgio Calderari promoted to Group General Manager, responsible for Corporate, Business Development, R&D, Technical Affairs, Commercial, and Manufacturing functions Riccardo Braglia has been confirmed as CEO of the Helsinn Group. His role will focus on the Group's fundamental strategic tasks, including internal and external growth, and new market opening. Riccardo Braglia will also directly ...
Saint-Prex, Switzerland (ots) - Results from a phase III pivotal study sub-analyses reported in European Urology show that prostate cancer patients who received Firmagon® (degarelix) in the study have a statistically significant greater probability of PSA (prostate-specific-antigen) recurrence-free survival ...
Dublin, Ireland (ots) - Helsinn, the Swiss pharmaceutical group, announced today that its Dublin plant, Helsinn Birex Pharmaceuticals (HBP), has been awarded the Irish 2009 Responsible Care® Award for Waste Management by PharmaChemical Ireland, the industry association representing the Irish chemical and pharmaceutical sector. "Environmental protection is ...
Zug (ots) - The Swiss biopharmaceuticals company AmVac AG in Zug has joined forces with the long-term strategic investor V+ GmbH & Co Fonds 2 KG. The private equity company based in Dresden has invested CHF 1,500,000 in AmVac AG since the first half of 2009. Last week V+ GmbH & Co Fonds 2 KG announced their intention of acquiring further shares in AmVac AG to the sum of CHF 3,000,000.00. Michael Vogel, spokesman of the investment board: "We agree with boosting ...
Dublin, Ireland (ots) - Helsinn announces the completion of its state of the art Stability Centre at its Helsinn Birex Pharmaceuticals facility in, Dublin, Ireland. The new facility which has a total storage capacity of 24 cu meters, contains a range of stability chambers which will operate at ICH ...